A subsequent efficacy test in a thioacetamide (TAA)-induced liver fibrosis mouse model (Figure 1C) revealed that the administration of commercially available MFG-E8 effectively reduced the fibrotic area (Sirius red-stained area, Figure 1D,E) and downregulated the expression level of liver-fibrosis-related genes (Col1a1, Col1a2) (Figure 1F), as we previously demonstrated [5]. This evidence concerns the gene COL1A1 and Hepatic fibrosis.